• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin
ConclusionThis is the first long-term follow-up of BoNT-A treatment for upper limb spasticity involving a large cohort independent of industry. Quality of life was improved by treating upper limb spasticity with BoNT-A, even at 5 years post-stroke. Personalizing objectives of the treatment amplified its efficacy. BoNT-A was a powerful analgesic when pain was spasticity-related. Treating the spastic upper limb also improved balance and gait abilities.
Source: Annals of Physical and Rehabilitation Medicine - June 25, 2019 Category: Rehabilitation Source Type: research

Botuloscope: 1-year follow-up of upper-limb post-stroke spasticity treated with botulinum toxin
Conclusion. This is the first long-term follow-up of BoNT-A treatment for upper-limb spasticity involving a large cohort independent of industry. Quality of life was improved by treating upper-limb spasticity with BoNT-A, even at 5 years post-stroke. Personalizing objectives of the treatment amplified its efficacy. BoNT-A was a powerful analgesic when pain was spasticity-related. Treating the spastic upper limb also improved balance and gait abilities.
Source: Annals of Physical and Rehabilitation Medicine - June 22, 2019 Category: Rehabilitation Source Type: research

Cortical Activity Modulation by Botulinum Toxin Type A in Patients with Post-Stroke Arm Spasticity: Real and Imagined Hand Movement (P1.142)
CONCLUSIONS:Study of 2 age-matched groups with mild and severe weakness demonstrated different effect of BoNT-lowered spasticity on motor system engagement. Group A during movement imagery at maximum BoNT effect manifested deactivation of visual and default mode system, perhaps a change from visual to kinesthetic imagery, with cerebellum participating. Group B during movement also manifested motor pattern normalization, especially reduced activation extent.Study Supported by: IGA MH CR grant NT13575.Disclosure: Dr. Hlustik has nothing to disclose. Dr. Veverka has nothing to disclose. Dr. Hok has nothing to disclose. Dr. Tu...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hlustik, P., Veverka, T., Hok, P., Tudos, Z., Otruba, P., Krobot, A., Kanovsky, P. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation and Recovery Source Type: research